Is Insmed Inc (INSM) a risky stock?
As of July 21, 2026, Clavix grades Insmed Inc (INSM) B- for risk, a composite score of 69 out of 100 on an A+ to F scale, which puts INSM in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind INSM's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how INSM scores on each, as of July 21, 2026.
What's moving INSM's risk right now
Company-specific signals Clavix flags behind INSM's current grade, drawn from recent news and filings as of July 21, 2026.
The sustained long-term efficacy and safety data de-risks TPIP's path to Phase 3 and strengthens its commercial potential in the PAH market, which could support a higher long-term…
The sustained 24-month efficacy signal strengthens the clinical profile of TPIP as a potentially differentiated once-daily PAH therapy, supporting Insmed's pipeline value and its…
Wealthfront Advisers LLC boosted its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 84.2% during the first quarter, Holdings Channel reports. The institutional investor owne…
What a B- grade means
On the Clavix A+ to F scale, INSM's composite of 69 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell INSM or any security. Grades are risk indicators, not predictions of return. Data may be delayed.